MDWD — MediWound Ltd.

Summary of MediWound Ltd. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $1.9 million, down from $5.8 million in Q4 2024, primarily due to reduced development services revenue linked to the U.S. government shutdown.
• Gross Profit: $300,000 (14.9% of revenue) compared to $900,000 (15.5%) in the prior year.
• R&D Expenses: Increased to $4.5 million from $3.0 million, reflecting investment in the EscharEx VALUE Phase III study.
• SG&A Expenses: Decreased to $3.6 million from $4.0 million, mainly due to lower marketing and share-based compensation.
• Operating Loss: $7.8 million, up from $6.1 million in Q4 2024.
• Net Loss: $7.2 million ($0.56 per share) compared to $3.9 million ($0.36 per share) in the previous year.
• Full Year 2025 Revenue: $17.0 million, down from $20.2 million in 2024.
• Net Loss for 2025: $23.9 million ($2.10 per share), improved from $30.2 million ($3.30 per share) in 2024.
• Cash Position: $53.6 million as of December 31, 2025, up from $43.6 million at the end of 2024.

2. Strategic Updates and Business Highlights

• EscharEx Development: Enrollment is ongoing in the Phase III VALUE trial for venous leg ulcers (VLUs), targeting 216 patients across 40 sites in the U.S. and Europe, with completion expected by year-end 2026. Plans to expand the clinical program to include diabetic foot ulcers (DFUs) and pressure ulcers in 2026.
• NexoBrid Manufacturing: The expanded manufacturing facility is operational, increasing production capacity sixfold, with commercial availability expected in 2026 pending regulatory approvals. Adoption in the U.S. is growing, with over 70 burn centers utilizing the product.
• Collaborations: Notable partnerships with industry leaders such as B. Braun, Coloplast, and others enhance the clinical development of EscharEx.

3. Forward Guidance and Outlook

• Revenue Guidance for 2026: Projected between $24 million and $26 million, with expectations of $32 million to $35 million for 2027, and $50 million to $55 million for 2028. This assumes continued support from BARDA and the U.S. Department of War.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: Significant decrease in revenue for both Q4 and full-year 2025, attributed mainly to the U.S. government shutdown affecting new contracts.
• Increased Operating Loss: The operating loss widened due to higher R&D expenses and lower revenue.
• Regulatory Risks: Future revenue projections are contingent on regulatory approvals for the expanded manufacturing facility and ongoing clinical trials.
• Geopolitical Concerns: Ongoing conflict with Iran poses operational risks, although the company remains resilient.

5. Notable Q&A Insights

• NexoBrid Demand: There is significant pent-up demand for NexoBrid in international markets, but commercial output is contingent on regulatory approvals expected in 2026.
• BARDA and DOW Support: Future revenue is expected from BARDA and the Department of War, with no revenue recorded from BARDA in 2025.
• Pressure Ulcer Study: The company is initiating a small trial for pressure ulcers, which could significantly expand the market opportunity.
• Adaptive Trial Design: The VALUE trial includes provisions for adaptive adjustments based on interim analysis, which could impact timelines and costs if sample sizes need to be increased.

Overall, while MediWound Ltd. is navigating significant challenges, particularly related to revenue and regulatory approvals, it is also laying the groundwork for future growth through strategic clinical developments and partnerships.